| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Gain (loss) on sale of interest in projects | - | - | - | -1,086 |
| Loss from continuing operations before income taxes | -44,517 | -44,862 | -47,398 | -10,751 |
| Net loss from continuing operations | -44,517 | -44,862 | -47,398 | - |
| Net revenue | 10,663 | - | - | - |
| Cost of goods sold | 287 | - | - | - |
| Research and development | 564 | - | - | - |
| Selling, general and administrative | 326 | - | - | - |
| Total costs and expenses | 1,177 | - | - | - |
| Income from operations | 9,486 | - | - | - |
| Gain on sale transactions, net | -422 | - | - | - |
| Other income (expense), net | -78 | - | - | - |
| Net income (loss) from discontinued operations before income taxes | 8,986 | - | - | - |
| Net income from discontinued operations, net of tax (note 6) | 8,986 | 342,629 | -9,171 | - |
| Net income (loss) | -35,531 | 297,767 | -56,569 | -10,751 |
| Earnings per share, basic | -0.31 | 2.57 | -0.49 | -0.09 |
| Earnings per share, diluted | -0.31 | 2.57 | -0.49 | -0.09 |
| Weighted average number of shares outstanding, basic | 116,229,170 | 116,077,710 | 115,857,780 | 115,210,091 |
| Weighted average number of shares outstanding, diluted | 116,229,170 | 116,077,710 | 115,857,780 | 115,210,091 |
Coherus Oncology, Inc. (CHRS)
Coherus Oncology, Inc. (CHRS)